Investigational drug · Phase 2
NRC-2694-A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NRC-2694-A"
First trial start
2022
Sep 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NRC-2694-A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma
- Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NRC-2694-A" as an intervention, largest first.
NATCO Pharma Ltd.Industry
NCT05283226 · 21 participants (planned) · Start Sep 30, 2022 · Primary completion Dec 30, 2026
Drug: NRC-2694-A; Paclitaxel · For: Carcinoma; Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Sites: Fullerton, California; Los Angeles, California; Boca Raton, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Carcinoma
- Savolitinibhmpl-504, AZD6094Phase 311 trials
AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer
- STAR0602InvikafuspPhase 22 trials
Marengo Therapeutics, Inc. · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumors
- KVA12123Phase 21 trial
Kineta Inc. · Cancer, Solid Tumor, Melanoma
- ST-067Phase 21 trial
Simcha IL-18, Inc. · Cancer, Solid Tumor, Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.